Goldline Pharmaceutical Limited is set to launch its Initial Public Offering (IPO).
It is a marketer and distributor of off-patent pharmaceutical products operating on an asset-light, third-party manufacturing model.
The public issue will open for subscription on Tuesday, May 12, 2026, and close on Thursday, May 14, 2026. Track all the IPOs of 2026 at our latest IPO section.
Through this 100% fresh issue book-built offering, the company aims to raise approximately ₹11.61 Crores at the price band of ₹41 – ₹43 per equity share.
The proceeds will be strategically utilized for debt reduction and general corporate purposes.
In this article, you will find Goldline Pharmaceutical IPO GMP today, price band, and a detailed review with valuation, strength and risks and financial performance. For subscription status of this and other IPOs, check our detailed IPO subscription status page.
Goldline Pharmaceutical IPO Details:
- Price Band: ₹41 – ₹43 per equity share
- Face Value: ₹10 per share
- IPO Open / Close Dates: May 12, 2026 – May 14, 2026
- Lot Size: 3,000 Shares (Note: Retail Minimum Application is 2 Lots / 6,000 Shares)
- Issue Size: 27,00,000 Equity Shares / ~₹11.61 Crores
- Fresh Issue: 100% Fresh Issue
- Registrar: Bigshare Services Pvt. Ltd.
- Listing Exchange: BSE SME
IPO Reservation: The offering comprises 27,00,000 shares, reserved as follows:
- QIB Portion: Up to 12,72,000 Equity Shares (Anchor Investors may be allocated up to 7,32,000 Equity Shares).
- NII (HNI) Portion: Up to 3,90,000 Equity Shares.
- Retail (RII) Portion: Up to 9,00,000 Equity Shares.
- Market Maker: 1,38,000 Equity Shares.
For issues with registrar and how to resolve check our detailed Bigshare IPO allotment guide which has all the important things for investors.
What Is The Goldline Pharmaceutical IPO GMP Today?
GMP changes daily and sometimes manytimes throughout the day, for the latest gmp, check our regularly updated latest gmp section.
And for gmp and listing relation visit our gmp vs listing accuracy study of 2026.
Note: GMP is unregulated and unofficial.
What Are The Important Goldline Pharmaceutical IPO Dates & Allotment Schedule?
For investors planning their capital allocation, here is the critical timeline for the issue:
- IPO Open Date: Tuesday, May 12, 2026
- IPO Close Date: Thursday, May 14, 2026
- Basis of Allotment Date: Friday, May 15, 2026
- Refund Initiation Date: Monday, May 18, 2026
- Credit of Shares: Monday, May 18, 2026
- Listing Date: Tuesday, May 19, 2026
What Are The Objectives of Goldline Pharmaceutical IPO?
The company proposes to utilize the Net Proceeds from the Fresh Issue towards the following strategic purposes:
- Debt Repayment: A substantial allocation of ₹8.35 Crores is earmarked for the part or full repayment/prepayment of outstanding borrowings. This move will significantly reduce finance costs, directly improving net profitability, and free up internal accruals for future business growth.
- General Corporate Purposes: The remaining balance (capped at 15% of gross proceeds or ₹10.00 Crores, whichever is lower) will be deployed towards general corporate expenses, business development initiatives, and meeting unforeseen operational exigencies.
How is The Financial Performance of Goldline Pharmaceutical?
The following table summarizes the financial performance of the company based on restated financial statements.
(Figures in ₹ Crores)
Particulars | Period Ended 31 Dec 25 (9M) | FY 2024-25 | FY 2023-24 | FY 2022-23 |
Total Income | 21.41 | 28.06 | 23.57 | 19.85 |
Profit After Tax (PAT) | 2.22 | 2.83 | 1.80 | 0.26 |
EBITDA | 4.16 | 5.83 | 4.30 | 2.19 |
Total Borrowing | 9.47 | 11.03 | 11.13 | 10.83 |
Assets | 27.40 | 26.28 | 22.93 | 19.39 |
Source: RHP
Financial Analysis & Observations:
Total Income:
The company demonstrated steady revenue scaling, growing from ₹19.85 Crores in FY23 to ₹28.06 Crores in FY25.
This growth is driven by expanding its distribution network and capturing strong domestic demand for its off-patent pharmaceutical products under the "Goldline" brand.
Profit After Tax (PAT):
Profitability surged impressively, expanding from just ₹0.26 Crores in FY23 to ₹2.83 Crores in FY25.
The PAT margin improved from 1.29% to over 10% during this period, reflecting the highly scalable nature of its asset-light model where revenue growth outpaces fixed overheads.
EBITDA:
Operational efficiency is strong, with EBITDA more than doubling from ₹2.19 Crores in FY23 to ₹5.83 Crores in FY25.
The EBITDA margin expansion to 20.78% in FY25 highlights the company's ability to maintain healthy gross margins while utilizing third-party contract manufacturers.
Total Borrowing:
Debt levels have remained relatively stable, standing at ₹9.47 Crores by December 2025.
The planned utilization of ₹8.35 Crores from the IPO proceeds to repay debt will virtually deleverage the balance sheet, significantly enhancing the company's financial flexibility.
Assets:
The asset base expanded to ₹27.40 Crores by December 2025.
Being an asset-light company with no owned manufacturing facilities, this growth is largely fueled by an increase in current assets, specifically trade receivables and inventory, required to support higher sales volumes.
What Are The P/E Ratio and Peer Comparison?
Based on its Fiscal Year 2025 earnings per share (EPS) of ₹4.10, the IPO is priced at a Price-to-Earnings (P/E) multiple of approximately 10.49x at the upper end of the price band (₹43).
P/E Ratio = ₹43 (Price) / ₹4.10 (Earnings Per Share)
P/E Ratio ≈ 10.49x
Peer Comparison Table (FY 2024-25 Data):
Company | P/E Ratio | RoNW (%) | EPS (₹) | Total Revenue (₹ Lakhs) |
Goldline Pharmaceutical | 10.49 | 27.37 | 4.10 | 2,805.57 |
Mono Pharmacare Ltd | 7.57 | 9.90 | 1.75 | 16,834.49 |
Chandra Bhagat Pharma | 28.94 | 2.86 | 1.14 | 8,671.61 |
Industry Average | 18.26 | - | - | - |
Analysis:
Goldline Pharmaceutical is entering the market at a P/E multiple of approximately 10.49x based on its FY25 EPS.
When compared to the industry average P/E of 18.26x and listed peer Chandra Bhagat Pharma (28.94x), the issue appears to be priced at a discount.
More importantly, Goldline boasts a better Return on Net Worth (RoNW) of 27.37%, vastly outperforming Mono Pharmacare (9.90%) and Chandra Bhagat (2.86%), which suggests highly efficient capital utilization compared to its peers.
What is The Industry Outlook of Goldline Pharmaceutical?
Growth Potential: The Indian pharmaceutical industry is robust, projected to grow at 9-11% to reach US$ 65 billion by 2024 and US$ 130 billion by 2030. The domestic market for affordable, branded generics remains a high-growth segment.
Market Trends: Asset-light business models are gaining traction. By outsourcing manufacturing, companies like Goldline can focus capital and resources entirely on building strong distribution networks and brand equity in regional markets.
What Are The Strengths and Risks of Goldline Pharmaceutical IPO?
Strengths:
- Asset-Light Model: Relying 100% on third-party manufacturing eliminates heavy capital expenditure risks and allows for agile scaling.
- High Return Ratios: A stellar RoNW of 35.83% and ROCE of 38.45% in FY25 indicate exceptional management of shareholder funds.
- Deleveraging Plan: Using the majority of IPO funds for debt repayment will structurally improve net margins post-listing.
Risks:
- High Concentration: The top 5 customers account for over 77% of revenue. Geographically, over 70% of revenue relies on Maharashtra and Madhya Pradesh, exposing the company to regional risks.
- Manufacturing Dependency: Complete reliance on third-party contract manufacturers means the company is vulnerable to supply chain disruptions or quality control issues outside its direct control.
- Negative Cash Flows: The company reported a net decrease in cash in FY23 and the 9 months ending Dec 2025, driven by high trade receivables, indicating working capital stress.
Key Considerations for Investors
Investors should note the Minimum Investment structure.
- Minimum Application: The lot size is 3,000 Shares. Based on the data provided, the minimum application for Retail Individual Investors is 2 Lots (6,000 Shares), amounting to ₹2,58,000. Note: This investment amount exceeds the typical ₹2 Lakh retail limit, which implies this category effectively targets Small-HNI investors.
- Valuation: At ~10.5x P/E, the pricing leaves room for upside compared to industry peers, especially given the superior return ratios.
- Risk Profile: While highly profitable, the severe customer concentration and complete reliance on third-party manufacturers are critical operational risks to weigh.
Key Takeaways
- IPO Price: ₹43 per share (Upper Band).
- Min Investment: ₹2,58,000 (6,000 Shares).
- Financials: Revenue ₹28 Cr (FY25);
- Allotment: May 15, 2026
- Listing: BSE SME platform on May 19, 2026.
FAQs on Goldline Pharmaceutical IPO
What is Goldline Pharmaceutical IPO GMP today?
For latest gmp check at our gmp today page.
What is Goldline Pharmaceutical IPO price band?
The price band is fixed at ₹41 to ₹43 per equity share.
What is Goldline Pharmaceutical IPO allotment date?
The allotment status is expected to be finalized on Friday, May 15, 2026.
How to check Goldline Pharmaceutical IPO allotment status?
Investors can check the status on the website of Bigshare Services Pvt. Ltd. (the Registrar) or via the BSE IPO allotment portal. For allotment details of other IPOs, check our ipo allotment page.
What is Goldline Pharmaceutical IPO listing date?
The shares are tentatively scheduled to list on Tuesday, May 19, 2026.
Investment Perspective on Goldline Pharmaceutical IPO
Goldline Pharmaceutical offers a high-return, asset-light opportunity in the growing domestic branded generics market. While the valuation is attractive relative to peers and the debt repayment strategy is solid, investors must be comfortable with the high ticket size, extreme customer concentration, and the inherent risks of outsourced manufacturing.
Disclaimer:
This article is strictly for educational purposes. Please consult a SEBI-registered investment advisor before making any investment decisions.
